Abstract Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are worldwide prevalent healthcareassociated pathogens. We have evaluated three Qiagen artus QS-RGQ assays for the detection of these pathogens. We examined 200 stool samples previously tested for C. difficile infection (CDI), 94 rectal swabs previously screened for VRE and 200 MRSA screening nasal swabs. With the routine diagnostic laboratory results being adopted as the gold standard, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the artus C. difficile assay were 100%, for the artus VanR QS-RGQ assay, 95, 68, 44 and 98%, and for the artus MRSA/SA assay, 80, 94, 93 and 83%, respectively. The artus VanR assay detected the vanA and/or vanB genes in 32% of culture-negative VRE screens; in 71% of these cases, only vanB was detected. An over-estimation of the rate of faecal VRE colonisation could be due to a patient population with high rates of faecal carriage of non-enterococcal species carrying vanB. Based on our findings, we conclude that all three artus QS-RGQ assays could be a useful addition to a diagnostic laboratory, and that the optimal choice of assay should be determined according to user needs.
Introduction
Healthcare-associated infections (HCAIs) are a major cause of morbidity and mortality [1] [2] [3] . HCAIs can affect patients in any type of setting where they receive care and represent the most frequent adverse event in healthcare delivery worldwide [4] . Recent systematic reviews have estimated hospital-wide prevalence of HCAIs in high-income countries at 7.6% and in low-and middle-income countries at 10.1% [4] . Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are three HCAI pathogens that are particularly prevalent worldwide.
Clostridium difficile infection (CDI) is considered the most common cause of nosocomial infectious diarrhoea among adults in the developed world [5] . The infection is related to antibiotic use and is associated with the overgrowth of C. difficile and the production of toxins A and/or B. These toxins cause a range of effects, including mild to severe diarrhoea, gut mucosal damage, colitis and pseudomembranous colitis. Recent figures report CDI as annually causing 1600 deaths in England and Wales, and 29,000 deaths in the USA [6, 7] . Since the clinical features of healthcare-associated diarrhoea cannot reliably distinguish C. difficile from other causes, laboratory confirmation is essential. UK and European guidelines on the diagnosis of CDI recommend glutamate dehydrogenase (GDH) enzyme immunoassay (EIA) or nucleic acid amplification testing (NAAT) to screen samples, followed by a sensitive toxin detection method [8] .
Vancomycin-resistant enterococci (VRE) are now amongst the most common HCAI multidrug-resistant organisms [9, 10] . Risk factors for nosocomial transmission of VRE include prolonged hospitalisation, use of broad-spectrum antimicrobials and prior surgery. VRE cause a range of infections, including bloodstream, intra-abdominal, surgical-site and urinary tract infections [9, 11] . Altogether, eight types of acquired vancomycin resistance genotypes are known in enterococci, with vanA being the most prevalent genotype worldwide, followed by vanB [12, 13] . Phenotypically, the vanA gene mediates a high level of resistance to vancomycin and teicoplanin, whereas the vanB gene confers low-to moderatelevel resistance to vancomycin only. Low-level vancomycin resistance expression, especially in vanB strains, may complicate the performance of diagnostic assays assessing the resistance phenotype and predicting the corresponding genotype. During recent years, clusters of infections and colonisations with vanB genotype Enterococcus faecium increased in a number of European countries [12] .
MRSA is an important cause of HCAIs and communityacquired infections [14, 15] . Patients colonised with MRSA serve as reservoirs for auto-infection and/or dissemination to other patients and healthcare workers [16, 17] . Conventional screening of MRSA is performed using selective and differential agar media, but the results are not available before 18-48 h and interpretation can be subjective. Faster detection can be achieved by using polymerase chain reaction (PCR)-based assays. There is ongoing debate regarding which tests are more appropriate for screening programmes. The increased cost of rapid tests may be offset by savings as a result of reduced cross-infection, fewer complications and better utilisation of beds [18, 19] .
Rapid and accurate detection of CDI, MRSA and VRE is required to ensure patients receive appropriate antimicrobial treatment and optimised infection prevention interventions. QIAGEN has developed real-time, multiplex, PCR assays for the detection of these three HCAI pathogens. The artus C. difficile QS-RGQ assay (CE marked and FDA cleared) detects the tcdA and tcdB genes that encode for C. difficile toxin A and toxin B, respectively; the artus VanR QS-RGQ (CE marked) assay detects the vanA and vanB genes of enterococci; the artus MRSA/SA QS-RGQ assay (CE marked) detects the lhd1, mecA and mecC genes of MRSA. We have evaluated the performance of these three molecular assays in comparison with conventional testing methods.
Materials and methods
We compared the performance of the QIAGEN artus assays (QIAGEN, GmbH, Hilden, Germany) with the routine identification methods at the Leeds Teaching Hospitals NHS Trust (LTHT) Microbiology Department. The artus assays were performed on the automated QIAsymphony RGQ system (QIAGEN). All samples tested were selected from those submitted to the routine laboratories.
Qiagen artus C. difficile assay A total of 200 stool samples received by the routine enteric laboratory between December 2013 and May 2014 from patients aged ≥2 years was selected for inclusion in the study. All samples were diarrhoeal (adopting the shape of the container), had been submitted for GDH detection and cytotoxin testing (CTT), and had sufficient material to allow for all testing required. The study set comprised 100 specimens previously found to be positive for both GDH antigen and cytotoxin production, and 100 GDH-negative specimens. Samples previously GDH-and cytotoxinpositive were between 1 day and 4 months old at the time of testing; negative samples were processed within 1 week of collection. All samples were stored at 2-5°C prior to testing. Samples were processed with the artus C. difficile QS-RGQ assay according to the manufacturer's instructions. Previously GDH/CTT-positive stool samples were re-analysed for the GDH antigen using the C. DIFF CHEK-60 GDH assay (TechLab, Blacksburg, VA, USA) according to the manufacturer's instructions, and also for the presence of cytotoxin. In brief, stool samples were first diluted 1:5 in phosphate-buffered saline before being centrifuged, and 20 μl of supernatant were then added to duplicate Vero cell monolayers. Once these had been protected by the addition of 20 μl of Clostridium sordellii antitoxin (Pro-Lab Diagnostics, UK), Vero cells were grown in 96-well flat-bottomed microtitre trays in 160 μl of Dulbecco medium. A positive result was recorded if cell rounding was observed in the unprotected cells only, after 24 or 48 h of incubation at 37°C in the presence of CO 2 .
Qiagen artus VanR QS-RGQ assay
Twenty rectal swabs positive for VRE, as determined by culture on kanamycin aesculin azide (KAA) agar plus vancomycin (E&O Laboratories, Bonnybridge, Scotland) and subsequent matrix-assisted laser desorption/ionisation time-offlight (MALDI-TOF) analysis, were collected from inpatients during April and May 2014. A further 74 VRE culturenegative rectal swabs collected during this period were also examined. Transport swabs containing Amies medium with charcoal were used (Thermo Fisher Scientific, Loughborough, UK). All samples were stored at 2-5°C prior to analysis and were processed using the artus VanR QS-RGQ assay as per the manufacturer's instructions.
Qiagen artus MRSA QS-RGQ assay
In total, 200 nasal swabs processed by the MRSA screening laboratory between January and June 2014 were retrospectively selected for inclusion in the study. Transport swabs containing Amies medium with charcoal were used (Thermo Fisher Scientific, Loughborough, UK). One hundred of these samples had previously been determined as MRSA-positive and 100 MRSA-negative, by culture on Brilliance MRSA 2 Agar (Oxoid, Basingstoke, UK). All samples were stored at 2-5°C prior to analysis. The MRSA-positive samples were between 3 weeks and 5 months old at the time of testing; all negative samples were processed within 1 week. Previously MRSApositive samples were first inoculated onto Brilliance MRSA 2 culture medium and subsequently processed using the artus MRSA QS-RGQ assay. Previously MRSA-negative swabs were processed with the artus assay but were not inoculated onto the culture medium. Sample preparation for the artus assay involved placing the swabs into tubes containing 2.5 ml of eNat medium (Copan, Brescia, Italy), followed by vigorous swirling. The eNat tubes were then placed directly onto the QIAsymphony instrument and the assay performed according to the manufacturer's instructions. Residual sample volumes within the eNat tubes following analyses were processed using the Xpert SA Nasal Complete assay (Cepheid, Sunnyvale, CA, USA) on the GeneXpert automated platform according to manufacturer's instructions.
Results

Qiagen artus C. difficile assay
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the artus C. difficile assay were all 100% [95% confidence interval (CI) 95-100%] when the original results of the diagnostic laboratory algorithm (GDH/CTT) were adopted as the gold standard. Of the 100 GDH/CTT-positive samples re-tested against this algorithm, 96% remained both GDH-and CTT-positive. A breakdown of the discrepant results is displayed in Table 1 .
Qiagen artus VanR QS-RGQ assay
The sensitivity, specificity, PPV and NPV of the artus VanR QS-RGQ assay were 95% (19/20, 95% CI 73-100%), 68% (50/74, 95% CI 56-78%), 44% (19/43, 95% CI 29-60) and 98% (50/51, 95% CI 88-100%), respectively, where direct culture followed by MALDI-TOF analysis was adopted as the gold standard. The assay detected the vanA and/or vanB genes in 32% of culture-negative VRE screens. In 71% of these cases (n = 17), only vanB was detected; in 25% of cases (n = 6), both vanA and vanB were detected, with vanA alone being detected in the remaining 4% (n = 1).
Qiagen artus MRSA QS-RGQ assay
Of the 200 nasal swabs previously analysed for the presence of MRSA by culture, eight MRSA-positive and 32 MRSAnegative swabs gave either an invalid result (n = 19) or an error message (n = 21) with the Xpert SA Nasal Complete assay. The majority of the errors (95%) were due to probe check failures. This was most likely due to the off-label nature of the methodology, specifically the charcoal content of the swab transport medium. These samples were eliminated from the study and results from the remaining 160 nasal swabs analysed. Adopting the original culture results as the gold standard, the sensitivity, specificity, PPV and NPV for the artus assay were 64% (58/91, 95% CI 53-73%), 94% (64/ 68, 95% CI 85-98%), 94% (58/62, 95% CI 84-98%) and 66% (64/97, 95% CI 56-75%), respectively, and for the Xpert assay, 74% (67/91, 95% CI 63-82%), 97% (66/68, 95% CI 89-99%), 97% (67/69, 95% CI 89-99%) and 73% (66/90, 95% CI 72-90%). The distribution of results obtained from both PCR assays is displayed in Table 2 . A total of 31 (19.4%) samples gave discordant results. The majority of discrepancies were results which were interpreted by the artus assay as S. aureus but designated 'not detected' by the Xpert assay (39%), followed by results interpreted as MRSA by the Xpert assay but designated S. aureus by the artus assay (32%). The majority of the results from this latter group (9/10) were found to be MRSA-positive by culture.
Of the 92 MRSA-positive swabs, only 71% were positive upon re-culture. There was good correlation between samples which were MRSA-positive upon re-culture and those samples which were MRSA-positive with one or both PCR assays. A second set of statistics was, therefore, calculated following the elimination of results from all swabs that were MRSA-negative upon re-culturing; the sensitivity, specificity, PPV and NPV for the artus assay were, then, 80% (52/65, 95% CI 68-89%), 94% (64/68, 95% CI 85-98%), 93% (52/ 56, 95% CI 82-98%) and 83% (64/77, 95% CI 72-90%), and for the Xpert assay, 88% (57/65, 95% CI 77-94%), 97% (66/ 
Discussion
There is still conflicting opinion on the optimal diagnosis of CDI worldwide [20] [21] [22] [23] . Inaccurate laboratory results may lead to unnecessary treatment and isolation, and the true cause of the patients' diarrhoea not being further investigated (in the case of false-positives) or cross-infection may occur with other patients and overtreatment with empirical antibiotics (in false-negative cases). A GDH test or NAAT are recommended for initial screening of samples because of their very high sensitivities, reported to be in the range 79.5-100% [8, 23, 24] , followed by a sensitive toxin detection assay. In this study, the performance of the artus C. difficile QS-RGQ assay was equivalent to that of a recommended two-step algorithm when testing samples retrospectively. A limitation of the study was that GDH-positive/CTT-negative samples were not included within the evaluation. However, although the sample selection is not necessarily representative of that seen in a routine hospital setting due to the proportion of positive samples being preselected, this is a useful evaluation of assay performance for the detection of true CDI-positives and true CDI-negatives. It is possible that excluding GDHpositive/CTT-negative samples may have slightly improved the performance of the artus C. difficile assay; however, this comparison most likely gives a more meaningful result in the context of CDI diagnosis, as such results do not represent CDI but possible colonisation.
It was noted that, in previously CTT-positive samples that were toxin-negative upon re-testing, it had either taken 48 h for a cytotoxic effect to occur in the initial test or this effect had only been observed with an undiluted sample. This suggests that there were low levels of toxin in these samples. It is possible that toxin degradation during storage may have lowered the concentration further to an undetectable level. As PCR assays detect the presence of the toxin genes as opposed to the presence of free toxin, the artus assay has potential to identify faecal samples as toxin gene-positive when they contain low toxin levels that are undetectable by CTT. Studies by Jazmati et al. [25] and Moon et al. [26] found the performance of the artus C. difficile assay to be comparable to that of the Xpert C. difficile PCR assay. It must be considered that a proportion of hospitalised patients may have toxigenic C. difficile with asymptomatic carriage and diarrhoea due to another cause. However, although a number of publications recommend that NAAT should not be used alone to diagnose CDI [8, 24, 27, 28] , some studies have found good correlation between toxin gene detection and the clinical status of the patient [29, 30] .
As the artus C. difficile assay (as with the further two artus assays evaluated) has a short turnaround time (3 h 40 min for 24 samples, which includes approximately 30-40 min handson time), is user-friendly, includes simple interpretation of results, has a high throughput (up to 72 per run) and offers flexibility of the associated platform for the detection of other organisms, this assay is a useful addition to the detection of CDI. As there is still no internationally accepted single method for CDI diagnosis, individual laboratories must decide which test will integrate best into their existing workflow. Two-or three-step approaches to the diagnosis of CDI could increase laboratory costs, but these might be offset by reduced total healthcare costs.
VRE
As with CDIs, rapid and accurate detection of VRE is essential for adequate patient management, including infection prevention measures. Traditional culture-based methods to detect these organisms are often time-consuming, taking up to several days to complete. A number of NAAT assays are now available that can detect either the vanA gene or both vanA and vanB genes. Assays detecting both of these genes are desirable, as a number of European countries have reported increasing numbers of colonisations and infections with vanBtype VRE [12, 31] . The sensitivity of the artus VanR assay in our study (95%) compares favourably with NAAT in previous studies [32] . Although the assay specificity was low (44%), it is possible that the false-positives recorded actually represented genuine VRE-positive samples, where bacterial growth was not supported by the culture medium. High rates of vanB carriage have previously been reported in the absence of cultivable VRE in faecal/rectal samples and have mostly been attributed to one of two explanations. The first is that vanB-type resistance is sometimes difficult to detect, since the vancomycin minimum inhibitory concentration (MIC) of these strains can be below the antimicrobial susceptibility breakpoint of ≤4 mg/ l defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [31, 33, 34] . Secondly, non-enterococcal vanB genes could result in positive PCR results. These can be found in the gut, especially in anaerobic bacteria like Clostridium species [32, [35] [36] [37] . In our study, the vanB gene alone was detected in 71% of these false-positive samples; our culture medium contained 6 mg/l vancomycin, and, so, either of these explanations is feasible. The artus VanR QS-RGQ assay may, indeed, be more sensitive for the detection of VRE isolates than culture due to the amplification of both vanA and vanB genes. However, further investigations on vanB-positive (but vanA-negative) isolates are needed to further knowledge here. If a patient population has high rates of faecal carriage of non-enterococcal species that contain vanB, an over-estimation of the rate of faecal VRE colonisation could result and potentially lead to unnecessary utilisation of hospital resources and infection control prevention measures.
MRSA
Rapid and accurate detection of MRSA is required to minimise the spread of this organism in healthcare settings. Active screening currently forms an integral part of many MRSA infection control and prevention strategies, with several NAAT assays available for this purpose.
Although the sensitivity values and NPVs of the artus and Xpert assays were low when calculated using the whole sample set, these values were much improved when the 33% of swabs originally MRSA culture-positive, but negative upon re-culture, were eliminated from the calculations. It is likely that bacterial degradation occurred during storage, and, so, these improved figures are more likely representative of assay performance during prospective testing. Our study was performed using an off-label method that incorporated charcoalcontaining transport swabs. The invalid samples and the error messages from the Xpert assay were presumed to be due to interfering or inhibiting factors within the charcoal. The sensitivity of the Xpert assay (88%) is comparable to those of other MRSA PCR assays (82-93%), although the sensitivity of the artus assay was slightly lower at 80%.
The specificities of both assays were relatively high (94 and 97% for the artus and Xpert assays, respectively) and compare well with other studies (78-99%) [38] [39] [40] [41] [42] . In most cases (80.5-90.5%), the two assays were in agreement as to whether MRSA, methicillin-susceptible Staphylococcus aureus (MSSA) or no targets were present. The most common discordant combination was MSSA detected by the artus assay but no targets detected by the Xpert assay (12/160). However, in an MRSA screening programme, this would not affect patient management. The second most common discordant category was where the artus assay detected MSSA but the Xpert assay detected MRSA (10/160). Such results would affect patient management and are, therefore, of greater concern. Almost all (9/10) of these samples were MRSA-positive by culture, which suggests that the artus assay misidentified these samples. The Xpert assay, unlike the artus assay, does not detect mecC variants; however, only 2.6% of samples were designated MRSA by the artus assay only and 3/4 of these were culture-negative. This study, therefore, does not highlight the lack of detection of mecC variants as a significant issue. Although the Xpert assay is rapid and simple to use when processing smaller sample volumes, the artus assay is more efficient when processing larger volumes and is less costly per test.
As with the artus C. difficile and VanR assays, the optimal choice of assay for MRSA screening should be determined according to user needs; for example, the artus MRSA assay would be more suited to a laboratory handling high volumes of screening swabs. The three artus assays all have high NPVs and are, therefore, especially suited to screening programmes. The assays can facilitate elimination of negative samples, meaning that confirmatory tests are only needed on a small proportion of these. This could reduce the hands-on time required overall and lead to negative results being released more quickly. Additional laboratory-specific factors, including financial considerations and technical expertise, will also be important in deciding between screening methods.
